CDH17 Protein, Cynomolgus, Recombinant (His)

Catalog No. TMPK-00555 Copy Product Info

Liver-intestine cadherin (CDH17) has been known to function as a tumor stimulator and diagnostic marker for almost two decades.In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC therapeutic approach. CDH17 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 89.2 kDa and the accession number is A0A2K5X8I8.

CDH17 Protein, Cynomolgus, Recombinant (His)

Catalog No. TMPK-00555

Copy Product Info

CDH17 Protein, Cynomolgus, Recombinant (His)

Pack Size	Price	USA Stock	Global Stock
5 μg	$63	7-10 days	7-10 days
10 μg	$100	7-10 days	7-10 days
20 μg	$163	7-10 days	7-10 days
50 μg	$318	7-10 days	7-10 days
100 μg	$533	7-10 days	7-10 days
200 μg	$969	7-10 days	7-10 days
500 μg	$2,130	7-10 days	7-10 days

Add to Cart

Add to Quotation

For In stock only · Estimated delivery:USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Anti-CDH17 Antibody captured on CM5 Chip via Protein A can bind Cynomolgus CDH17, His Tag with an affinity constant of 13.44 nM as determined in SPR assay.
Description	Liver-intestine cadherin (CDH17) has been known to function as a tumor stimulator and diagnostic marker for almost two decades.In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC therapeutic approach. CDH17 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 89.2 kDa and the accession number is A0A2K5X8I8.
Species	Cynomolgus
Expression System	HEK293 Cells
Tag	C-His
Accession Number	A0A2K5X8I8
Synonyms	P130,MGC142024,MGC138218,LI-cadherin,HPT-1,FLJ26931,Cdh17,CDH16,Cadherin-17,cadherin-16,BILL-cadherin
Construction	Met1-Met795
Protein Purity	> 90% as determined by Tris-Bis PAGE
Molecular Weight	89.2 kDa (predicted). Due to glycosylation, the protein migrates to 105-115 kDa based on Tris-Bis PAGE result.
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (PH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	Liver-intestine cadherin (CDH17) has been known to function as a tumor stimulator and diagnostic marker for almost two decades.In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC therapeutic approach.